EA201792520A2 - Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор - Google Patents

Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор

Info

Publication number
EA201792520A2
EA201792520A2 EA201792520A EA201792520A EA201792520A2 EA 201792520 A2 EA201792520 A2 EA 201792520A2 EA 201792520 A EA201792520 A EA 201792520A EA 201792520 A EA201792520 A EA 201792520A EA 201792520 A2 EA201792520 A2 EA 201792520A2
Authority
EA
Eurasian Patent Office
Prior art keywords
androgen receptor
methods
modified
compositions
receptor polypeptides
Prior art date
Application number
EA201792520A
Other languages
English (en)
Other versions
EA035535B1 (ru
EA201792520A3 (ru
Inventor
Джеймс Дэвид Джозеф
Джеффри Х. Хэджер
Джон Ли Сенсинтаффар
Нхин Лу
Цзин Циань
Николас Д. Смит
Original Assignee
Арагон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арагон Фармасьютикалз, Инк. filed Critical Арагон Фармасьютикалз, Инк.
Publication of EA201792520A2 publication Critical patent/EA201792520A2/ru
Publication of EA201792520A3 publication Critical patent/EA201792520A3/ru
Publication of EA035535B1 publication Critical patent/EA035535B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Abstract

В настоящем документе описаны модифицированные полипептиды андрогенного рецептора, которые являются резистентными к ингибированию ингибитором андрогенного рецептора. В настоящем документе описаны композиции, комбинации и наборы, содержащие модифицированные полипептиды андрогенного рецептора, а также способы применения модифицированных полипептидов андрогенного рецептора. В настоящем документе также описаны способы применения модифицированных полипептидов андрогенного рецептора в качестве агентов скрининга для выявления и конструирования модуляторов андрогенного рецептора третьего поколения. В настоящем документе также описаны модуляторы андрогенного рецептора третьего поколения, которые ингибируют активность модифицированных полипептидов андрогенного рецептора. Также описаны фармацевтические композиции и лекарственные средства, которые включают описанные в настоящем документе соединения, а также способы применения таких модуляторов андрогенного рецептора самостоятельно или в комбинации с другими соединениями для лечения заболеваний или состояний, включая онкологические заболевания, такие как кастрационно-резистентный рак предстательной железы, которые опосредованы или зависят от андрогенных рецепторов.
EA201792520A 2012-07-27 2013-07-26 Слитый белок и устройство для лечения заболеваний или состояний, связанных с андрогенными рецепторами EA035535B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676842P 2012-07-27 2012-07-27
US201361783763P 2013-03-14 2013-03-14
US201361829123P 2013-05-30 2013-05-30

Publications (3)

Publication Number Publication Date
EA201792520A2 true EA201792520A2 (ru) 2018-04-30
EA201792520A3 EA201792520A3 (ru) 2018-08-31
EA035535B1 EA035535B1 (ru) 2020-07-01

Family

ID=48948536

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792520A EA035535B1 (ru) 2012-07-27 2013-07-26 Слитый белок и устройство для лечения заболеваний или состояний, связанных с андрогенными рецепторами
EA201590290A EA029563B1 (ru) 2012-07-27 2013-07-26 Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201590290A EA029563B1 (ru) 2012-07-27 2013-07-26 Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор

Country Status (34)

Country Link
US (2) US9617602B2 (ru)
EP (2) EP2877599B1 (ru)
JP (3) JP6297556B2 (ru)
KR (2) KR20210012064A (ru)
CN (3) CN110845626A (ru)
AU (3) AU2013295543B2 (ru)
BR (2) BR122017017921A2 (ru)
CA (1) CA2879926A1 (ru)
CL (1) CL2015000194A1 (ru)
CO (1) CO7280477A2 (ru)
CR (1) CR20150022A (ru)
CY (1) CY1122651T1 (ru)
DK (1) DK2877599T3 (ru)
EA (2) EA035535B1 (ru)
EC (1) ECSP15007420A (ru)
ES (1) ES2764381T3 (ru)
GT (1) GT201500019A (ru)
HK (1) HK1211060A1 (ru)
HR (1) HRP20192342T1 (ru)
HU (1) HUE047781T2 (ru)
IL (2) IL236844B (ru)
LT (1) LT2877599T (ru)
MX (2) MX370507B (ru)
NI (1) NI201500004A (ru)
NZ (4) NZ740700A (ru)
PE (3) PE20190845A1 (ru)
PH (2) PH12015500175A1 (ru)
PL (1) PL2877599T3 (ru)
PT (1) PT2877599T (ru)
RS (1) RS59812B1 (ru)
SG (2) SG11201500184TA (ru)
SI (1) SI2877599T1 (ru)
UA (1) UA118178C2 (ru)
WO (1) WO2014018926A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721506C (en) 2008-04-16 2019-09-17 Jun Luo Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
WO2013090921A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
US10202653B2 (en) 2012-04-20 2019-02-12 Cepheid Compositions and methods for detecting markers associated with bladder cancer
EP2912194B1 (en) * 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
CN105143463A (zh) 2013-02-25 2015-12-09 诺华股份有限公司 新的雄激素受体突变
CA2903104A1 (en) * 2013-03-06 2014-09-12 Cepheid Methods of detecting bladder cancer
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
AU2014306698A1 (en) 2013-08-12 2016-01-28 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
JP2016535013A (ja) 2013-10-18 2016-11-10 ドイチェス クレブスフォルシュンクスツェントルム 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
JP6666254B2 (ja) * 2014-02-05 2020-03-13 レツク・フアーマシユーテイカルズ・デー・デー アンドロゲン受容体アンタゴニストの固体医薬組成物
EP3146081B1 (en) 2014-05-19 2020-10-28 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
BR112018068937A8 (pt) 2016-03-29 2023-03-07 Hoffmann La Roche Método para operar um receptor para receber dados de analito, receptor e produto de programa de computador
CN106405085B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性***癌的elisa试剂盒及使用方法
CN106198985B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性***癌的elisa试剂盒及使用方法
CN106290919B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性***癌的elisa试剂盒及使用方法
CN106526185B (zh) * 2016-10-28 2018-03-30 拜尔康(天津)医药科技有限公司 用于检测去势抵抗性***癌的elisa试剂盒及检测方法
CA3046869C (en) 2016-12-16 2022-05-17 Kangpu Biopharmaceuticals, Ltd. Combination of a benzoheterocyclic compound and an androgen receptor pathway modulator for the treatment of prostate cancer
CA3078437A1 (en) * 2017-10-19 2019-04-25 Yale University Inhibition of androgen receptor by extracts of medicinal herbs and compositions thereof
CN108018342A (zh) * 2017-12-04 2018-05-11 合肥艾迪康临床检验所有限公司 检测ar基因突变的引物和方法
JP6993683B2 (ja) 2017-12-15 2022-01-13 東都興業株式会社 ビニールハウスにおけるシート押え紐の止め具
CN109115742A (zh) * 2018-09-05 2019-01-01 中国农业科学院农业质量标准与检测技术研究所 一种抗雄激素效应的检测方法
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
KR102473989B1 (ko) 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
JP2022549222A (ja) * 2019-09-23 2022-11-24 アキュター バイオテクノロジー インコーポレイテッド アンドロゲン受容体分解活性を有する新規尿素およびその使用
GB201914296D0 (en) * 2019-10-03 2019-11-20 Univ Oxford Innovation Ltd Treatment
WO2021110731A1 (en) * 2019-12-03 2021-06-10 Bayer Aktiengesellschaft Method for determining the response of prostate cancer patients to treatment with androgen receptor antagonists based on gene expression changes or super-enhancer protein-binding profiles
CN113533730B (zh) * 2021-07-23 2022-09-06 南方医科大学深圳医院 一种血浆外泌体标志物组合及其应用
WO2024001989A1 (en) * 2022-06-27 2024-01-04 Etern Biopharma (Shanghai) Co., Ltd. Compositions and methods for modulating molecules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0714410A4 (en) 1993-07-26 1997-08-20 K O Technology Inc GENE ALTERNATIVE ALLEH INHIBITORS USED AS A BASE FOR THERAPEUTIC AGENTS AGAINST CANCER
US6200754B1 (en) 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
GB0005689D0 (en) * 2000-03-09 2000-05-03 Schering Ag Crystal
AU8821301A (en) * 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
WO2005099693A2 (en) * 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
CN101932709B (zh) * 2007-11-26 2014-09-10 桑塔里斯制药公司 靶向雄激素受体的lna拮抗剂
EP2065474A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
US8133724B2 (en) * 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
JP5631382B2 (ja) * 2009-04-03 2014-11-26 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 複合材料の製造方法
JP2013508417A (ja) * 2009-10-23 2013-03-07 ヘルス リサーチ インコーポレイテッド アンドロゲン受容体陽性癌を処置する方法

Also Published As

Publication number Publication date
PL2877599T3 (pl) 2020-05-18
IL265610B (en) 2021-03-25
AU2013295543A1 (en) 2015-02-05
CO7280477A2 (es) 2015-05-29
HRP20192342T1 (hr) 2020-04-03
JP6592545B2 (ja) 2019-10-16
NZ744288A (en) 2020-04-24
US20170196840A1 (en) 2017-07-13
KR102210183B1 (ko) 2021-01-29
RS59812B1 (sr) 2020-02-28
WO2014018926A8 (en) 2014-04-10
MX2019015148A (es) 2020-02-19
EP2877599B1 (en) 2019-10-23
EA029563B1 (ru) 2018-04-30
MX370507B (es) 2019-12-16
JP2020072655A (ja) 2020-05-14
IL236844A0 (en) 2015-03-31
AU2019201726B2 (en) 2021-04-01
CN104685072A (zh) 2015-06-03
NZ742581A (en) 2020-02-28
PT2877599T (pt) 2020-01-24
AU2017203385B2 (en) 2018-12-20
JP2015531590A (ja) 2015-11-05
UA118178C2 (uk) 2018-12-10
MX2015001209A (es) 2015-09-23
PE20190845A1 (es) 2019-06-17
KR20150072399A (ko) 2015-06-29
EA201590290A1 (ru) 2015-06-30
PH12018502500A1 (en) 2020-09-14
DK2877599T3 (da) 2020-01-20
WO2014018926A1 (en) 2014-01-30
KR20210012064A (ko) 2021-02-02
AU2017203385A1 (en) 2017-06-08
PE20190574A1 (es) 2019-04-22
US9617602B2 (en) 2017-04-11
PH12015500175B1 (en) 2015-03-16
EA035535B1 (ru) 2020-07-01
BR112015001801A2 (pt) 2017-11-07
JP2018113968A (ja) 2018-07-26
PE20150644A1 (es) 2015-05-11
SG11201500184TA (en) 2015-04-29
EP3653733A1 (en) 2020-05-20
ECSP15007420A (es) 2016-01-29
IL265610A (en) 2019-05-30
JP6297556B2 (ja) 2018-03-20
CR20150022A (es) 2015-04-30
NZ704487A (en) 2018-05-25
CA2879926A1 (en) 2014-01-30
CN110845626A (zh) 2020-02-28
SI2877599T1 (sl) 2020-03-31
IL236844B (en) 2019-09-26
HK1211060A1 (en) 2016-05-13
HUE047781T2 (hu) 2020-05-28
LT2877599T (lt) 2020-01-27
PH12015500175A1 (en) 2015-03-16
SG10201703254VA (en) 2017-06-29
US20150252426A1 (en) 2015-09-10
EP2877599A1 (en) 2015-06-03
ES2764381T3 (es) 2020-06-03
CL2015000194A1 (es) 2015-04-24
CN108048567A (zh) 2018-05-18
CY1122651T1 (el) 2021-03-12
NI201500004A (es) 2015-10-05
NZ740700A (en) 2019-07-26
EA201792520A3 (ru) 2018-08-31
BR122017017921A2 (pt) 2019-09-10
AU2013295543B2 (en) 2019-03-14
AU2019201726A1 (en) 2019-04-04
GT201500019A (es) 2017-07-24

Similar Documents

Publication Publication Date Title
EA201792520A3 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
EA201170155A1 (ru) Специфические антагонисты рецептора fgf-r4
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
NZ761094A (en) Diaryl macrocycles as modulators of protein kinases
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
EA201991772A1 (ru) Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
EA201691568A1 (ru) Твердые фармацевтические композиции антагонистов рецепторов андрогенов
CR20170216A (es) Composiciones anticancerígenas
PH12019502692A1 (en) Anti-cancer combination therapy
CR20170218A (es) Composiciones anticancerígenas
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA201591967A1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
EA201792380A1 (ru) Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен
EA202090782A1 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
EA201992835A1 (ru) Противораковая комбинированная терапия